144 related articles for article (PubMed ID: 35851185)
1. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.
Krajewski W; Aumatell J; Subiela JD; Nowak Ł; Tukiendorf A; Moschini M; Basile G; Poletajew S; Małkiewicz B; Del Giudice F; Maggi M; Chung BI; Cimadamore A; Galosi AB; Fave RFD; D'Andrea D; Shariat SF; Hornak J; Babjuk M; Chorbińska J; Teoh JY; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Panunzio A; Alvarez-Maestro M; Simone G; Mastroianni R; Łaszkiewicz J; Lonati C; Zamboni S; Simeone C; Niedziela Ł; Candela L; Macek P; Contieri R; Hidalgo BG; Rivas JG; Sosnowski R; Mori K; Mir C; Soria F; González-Padilla DA; Faba ÒR; Palou J; Ploussard G; Rajwa P; Hałoń A; Laukhtina E; Pradere B; Tully K; Burgos FJ; Cidre MÁJ; Szydełko T;
Urol Oncol; 2022 Nov; 40(11):491.e11-491.e19. PubMed ID: 35851185
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.
Xylinas E; Kent M; Kluth L; Pycha A; Comploj E; Svatek RS; Lotan Y; Trinh QD; Karakiewicz PI; Holmang S; Scherr DS; Zerbib M; Vickers AJ; Shariat SF
Br J Cancer; 2013 Sep; 109(6):1460-6. PubMed ID: 23982601
[TBL] [Abstract][Full Text] [Related]
3. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.
Jobczyk M; Stawiski K; Fendler W; Różański W
Cancer Med; 2020 Jun; 9(11):4014-4025. PubMed ID: 32216043
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of EORTC And CUETO Risk Tables in Terms of the Prediction of Recurrence and Progression in All Non-Muscle-Invasive Bladder Cancer Patients.
Dalkilic A; Bayar G; Kilinc MF
Urol J; 2019 Feb; 16(1):37-43. PubMed ID: 30120763
[TBL] [Abstract][Full Text] [Related]
5. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
Ravvaz K; Walz ME; Weissert JA; Downs TM
J Urol; 2017 Oct; 198(4):824-831. PubMed ID: 28433642
[TBL] [Abstract][Full Text] [Related]
6. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
7. Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guérin Therapy in Non-Muscle-Invasive Bladder Cancer.
Ślusarczyk A; Garbas K; Pustuła P; Zapała Ł; Radziszewski P
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730636
[TBL] [Abstract][Full Text] [Related]
8. Validation of the CUETO scoring model for predicting recurrence and progression in T1G3 urothelial carcinoma of the bladder.
Krajewski W; Rodríguez-Faba O; Breda A; Pisano F; Poletajew S; Tukiendorf A; Zdrojowy R; Kołodziej A; Palou J
Actas Urol Esp (Engl Ed); 2019 Oct; 43(8):445-451. PubMed ID: 31155372
[TBL] [Abstract][Full Text] [Related]
9. Performance of the EORTC and CUETO Models to Predict Recurrence and Progression in High-risk Non-muscle-invasive Bladder Cancer Patients.
Pazır Y; Esmeray A; Gelmis M; Caglar U; Ozgor F; Sarılar O; Akbulut F
Urol J; 2024 May; 21(3):169-174. PubMed ID: 38493314
[TBL] [Abstract][Full Text] [Related]
10. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
Zhang G; Steinbach D; Grimm MO; Horstmann M
World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
[TBL] [Abstract][Full Text] [Related]
11. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
[TBL] [Abstract][Full Text] [Related]
12. Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models.
Xu T; Zhu Z; Zhang X; Wang X; Zhong S; Zhang M; Shen Z
Urology; 2013 Aug; 82(2):387-93. PubMed ID: 23759377
[TBL] [Abstract][Full Text] [Related]
13. Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models.
Choi SY; Ryu JH; Chang IH; Kim TH; Myung SC; Moon YT; Kim KD; Kim JW
Korean J Urol; 2014 Oct; 55(10):643-9. PubMed ID: 25324946
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
15. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Patients with Non-Muscle Invasive Bladder Cancer treated with Intravesical Bacillus Calmette-Guérin and the Relationship with the CUETO Scoring Model.
Chung JW; Kim JW; Lee EH; Chun SY; Park DJ; Byeon KH; Choi SH; Lee JN; Kim BS; Kim HT; Yoo ES; Kwon TG; Ha YS; Kim TH
Urol J; 2021 Oct; 19(4):281-288. PubMed ID: 34655075
[TBL] [Abstract][Full Text] [Related]
17. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Sylvester RJ; Kamat AM
Eur Urol Oncol; 2022 Feb; 5(1):84-91. PubMed ID: 34920986
[TBL] [Abstract][Full Text] [Related]
18. Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups.
Piao XM; Kim SK; Byun YJ; Zheng CM; Kang HW; Kim WT; Kim YJ; Lee SC; Kim WJ; Moon SK; Choi YH; Yun SJ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430959
[TBL] [Abstract][Full Text] [Related]
19. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Ojea A; Portillo J; Montesinos M; Gonzalez M; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
Eur Urol; 2011 Sep; 60(3):423-30. PubMed ID: 21621906
[TBL] [Abstract][Full Text] [Related]
20. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
